Drug Trial Radar · NCT01222052
6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Jun 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
4,150
Actual
Start
Jan 2002
Primary completion
Feb 2009
Study completion Feb 2019
Sponsor
- Lead sponsor
- Martin-Luther-Universität Halle-WittenbergAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GBG Forschungs GmbH
- First posted
- Oct 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In low-risk node-negative breast cancer patients adjuvant chemotherapy should be spared. The identification of this subgroup can be based either on clinical and pathological or on tumour-biological criteria. Due to their high prognostic impact, the tumour-biological invasion markers uPA/PAI-1 (urokinase-type plasminogen activator and its inhibitor PAI-1) are potential candidates to effectively assess the risk of relapse in node-negative breast cancer. This study is aimed to compare the risk assessment by the traditional clinico-pathological factors and by tumour-biological factors. The second study question refers to the comparison between an adjuvant combination treatment with FE100C\*6 and a sequential treatment with FE100C\*3 and Docetaxel\*3.
Conditions
- Breast Cancer
Interventions
5-Fluorouracil, Epirubicin, Cyclophosphamide, DocetaxelDrug
Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free SurvivalTime frame: after 10 years follow up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GBG Forschungs GmbH
Neu-Isenburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.